Genor Biopharma Holdings (HKSE:06998) Other Net Income (Loss) : HK$0.0 Mil (TTM As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Genor Biopharma Holdings Other Net Income (Loss)?

Genor Biopharma Holdings's Other Net Income (Loss) for the six months ended in Dec. 2024 was HK$0.0 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2024 was HK$0.0 Mil.

Genor Biopharma Holdings's quarterly Other Net Income (Loss) declined from Dec. 2023 (HK$0.0 Mil) to Jun. 2024 (HK$0.0 Mil) and declined from Jun. 2024 (HK$0.0 Mil) to Dec. 2024 (HK$0.0 Mil).

Genor Biopharma Holdings Other Net Income (Loss) Historical Data

The historical data trend for Genor Biopharma Holdings's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genor Biopharma Holdings Other Net Income (Loss) Chart

Genor Biopharma Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Net Income (Loss)

Get a 7-Day Free Trial

Genor Biopharma Holdings Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Other Net Income (Loss)	Get a 7-Day Free Trial							-	-	-	-	-

Genor Biopharma Holdings Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.0 Mil.

Genor Biopharma Holdings Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Genor Biopharma Holdings's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Genor Biopharma Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genor Biopharma Holdings Ltd (HKSE:06998) » Definitions » Other Net Income (Loss)

Comparable Companies

Traded in Other Exchanges

67N:Germany

Address

690 Bibo Road, Room 401-17, Building 6, Pudong New District, Shanghai, CHN, 201203

Website

https://www.genorbio.com

Genor Biopharma Holdings Ltd is a commercial-ready biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. The company is focused on therapeutic areas with substantial unmet medical needs in oncology, autoimmune, and other chronic diseases. Its key drug candidates include GB491 (lerociclib), a differentiated oral CDK4/6 inhibitor; GB221, a novel HER2 mAb drug candidate; geptanolimab (GB226), GB492, a STING agonist expected to exert synergistic effects in combination with GB226; GB242, an infliximab (Remicade) biosimilar; and GB223, a RANKL, and others.

Executives

Forebright New Opportunities Fund, L.p.	2101 Beneficial owner
Forbright Global Limited	2201 Interest of corporation controlled by you
Fnof Gp Limited	2201 Interest of corporation controlled by you
Deg – Deutsche Investitions- Und Entwicklungsgesellschaft Mbh	2101 Beneficial owner
Hsg Growth V Holdco Q, Ltd.	2101 Beneficial owner
Hsg Holding Limited	2201 Interest of corporation controlled by you
Snp China Enterprises Limited	2201 Interest of corporation controlled by you
Hongshan Capital Growth Fund Management I, L.p.	2201 Interest of corporation controlled by you
Shen Nan Peng	2201 Interest of corporation controlled by you
Hongshan Capital Growth Fund I, L.p.	2101 Beneficial owner
Hongshan Capital Growth Fund V, L.p.	2201 Interest of corporation controlled by you
Hsg Growth V Management, L.p.	2201 Interest of corporation controlled by you
Hongshan Capital Management I, L.p.	2201 Interest of corporation controlled by you
Hongshan Capital I, L.p.	2101 Beneficial owner
Ni Xin	2101 Beneficial owner

Genor Biopharma Holdings Headlines

No Headlines